Why the study?
Does trypanocidal therapy reduce mortality or progression to chronic chagasic cardiomyopathy in individuals with chronic asymptomatic Trypanosoma cruzi infection?
Does trypanocidal therapy reduce mortality or progression to chronic chagasic cardiomyopathy in individuals with chronic asymptomatic Trypanosoma cruzi infection?
Trypanocidal therapy in chronic asymptomatic Chagas disease reduces parasite-related outcomes, but evidence for preventing progression to cardiomyopathy or mortality remains low quality and inconclusive.
No takes yet. Share an insight, caveat, or question.
Does not support trypanocidal therapy to prevent CCC progression or mortality; leaves open need for definitive trials.
Villar et al. (2014) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: